NeuroVive physic and Hospices Civils de Lyon (HCL) announced the enrollment and care of the first patient in the insular multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's liberal CicloMulsionTM cremophor-free IV cyclosporine formulation is used in this study of 1,000 work undergoing percutaneous coronary action (PCI) for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue. The double-blind, placebo-controlled, investigator-initiated study is being led by trial sponsor tutor



if (lexico_globals.googleafc.ads.content.length)
{
document.write(lexico_globals.googleafc.ads.contenttop);
document.write(lexico_globals.googleafc.ads.sponsoredlinks);
document.write(lexico_globals.googleafc.ads.content[2]);
document.write("");
Michel Ovize, MD, PhD, of HCL...

More: - The rest...